Xilio Therapeutics Inc (XLO)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$8.71+0.35%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · XLO
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -81.4% |
| Our one-year growth estimate | diamond | -20.0% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 61.4 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-04 · Compared with 66 industry peers
XLO — director transition
Dated 2026-04-16
Director — Cheryl R. Blanchard, Ph.D.: Dr. Cheryl R. Blanchard was elected as a Class III director and appointed to the Compensation Committee and Audit Committee, succeeding Christina Rossi.
Why it matters: Starting the trial would show that Xilio moved its lead program from FDA clearance into testing in people.
Supportive ifXilio reports that it gave the first patient a dose in the XTX501 Phase 1 trial during the second half of 2026.
Worry ifBy December 31, 2026, Xilio has not started dosing, or reports a delay to the planned start.
Why it matters: Xilio reported $136.0 million in cash and a runway into Q1 2028. A shorter runway could raise funding pressure.
Worry ifOn November 12, Xilio says its cash will last at least through Q1 2028. This does not rely on warrant exercises or new funding.
Less concerning ifOn November 12, Xilio shortens its stated runway to before Q1 2028 or reports a need for new funding sooner.
Why it matters: These payments could add cash without a new share sale. Xilio cited up to $31.0 million in near-term payments.
Supportive ifXilio reports receiving an AbbVie milestone or option fee by June 30, 2027, adding to its cash balance.
Worry ifXilio reports no AbbVie milestone or option fee by June 30, 2027, and lowers its cash runway estimate.
Why it matters: The package could lead to an option decision and show whether the program can bring value through Xilio's Gilead deal.
Supportive ifXilio delivers the Phase 2 data package to Gilead by June 30, 2027, and reports that it met the agreed data terms.
Worry ifXilio delays delivery past June 30, 2027, or says the Phase 2 data do not support an option decision.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$101 on $10,000 · ±1.0% | How much price usually moves either way. |
| Bad day | $470 loss on $10,000 · 4.7% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,866 loss on $10,000 · 38.7% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.